Drug Trial Radar · NCT07079579
Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients
Last checked: Nov 20, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 2025
Primary completion
Jun 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the rationality of different initial doses of enarodustat for the treatment of anemia in ND-CKD patients
Conditions
- Renal Anemia in Non-dialysis Chronic Kidney Disease
Interventions
Enarodustat 2mgDrug
initial phase:2mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks
Enarodustat 3mgDrug
initial phase:3mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks
Enarodustat 4mgDrug
initial phase:4mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Hb level at Week 16 of treatmentTime frame: week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hosptial
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.